A new analysis included more than 110,000 adults with major depressive disorder (MDD) and treatment-resistant depression (TRD). Patients with TRD had total healthcare costs 1.5 times higher than those ...

One of the first real-world studies of psilocybin therapy suggests meaningful improvements in treatment-resistant depression outside the controlled setting of clinical trials.

Treatment-resistant major depression (TRD) is associated with a 17% higher risk for all-cause mortality than non-TRD major depressive disorder (MDD), a new study shows. The increased mortality risk ...

Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of disability and low quality of life. One in every three people suffering from MDD ...

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the ...

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD). TRD is defined by a ...

Denovo Neuroscience, a pioneer in applying precision medicine in central nervous system (CNS) diseases, today announced that members of the Company’s management team will present its biomarker guided ...

Laughing gas could offer rapid-acting treatment for depression, a study has found. Nitrous oxide, also known as laughing gas, is a colourless gas that is inhaled and commonly used as a painkiller. The ...

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the ...

TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for ...